ISHITADRPharmaceuticals
Ishita Drugs & Industries Ltd — Profit & Loss Statement
₹69.11
-11.27%
Ishita Drugs & Industries Ltd Profit & Loss Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Tax Effect Of Unusual Items | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Tax Rate For Calcs | 0.25 | 0.24 | 0.26 | 0.23 | — |
| Normalized EBITDA | 1.34 Cr | 1.19 Cr | 0.95 Cr | 1.18 Cr | — |
| Total Unusual Items | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Total Unusual Items Excluding Goodwill | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Income From Continuing Operation Net Minority Interest | 0.87 Cr | 0.75 Cr | 0.58 Cr | 0.80 Cr | — |
| Reconciled Depreciation | 0.11 Cr | 0.11 Cr | 0.13 Cr | 0.13 Cr | — |
| Reconciled Cost Of Revenue | 10.68 Cr | 11.29 Cr | 9.00 Cr | 10.71 Cr | — |
| EBITDA | 1.34 Cr | 1.19 Cr | 0.95 Cr | 1.18 Cr | — |
| EBIT | 1.23 Cr | 1.08 Cr | 0.82 Cr | 1.05 Cr | — |
| Net Interest Income | -0.07 Cr | -0.09 Cr | 0.09 Cr | 0.04 Cr | — |
| Interest Expense | 0.07 Cr | 0.09 Cr | 0.04 Cr | 42938.00 | — |
| Normalized Income | 0.87 Cr | 0.75 Cr | 0.58 Cr | 0.80 Cr | — |
| Net Income From Continuing And Discontinued Operation | 0.87 Cr | 0.75 Cr | 0.58 Cr | 0.80 Cr | — |
| Total Expenses | 14.11 Cr | 14.39 Cr | 11.44 Cr | 13.13 Cr | — |
| Diluted NI Availto Com Stockholders | 0.87 Cr | 0.75 Cr | 0.58 Cr | 0.80 Cr | — |
| Net Income Common Stockholders | 0.87 Cr | 0.75 Cr | 0.58 Cr | 0.80 Cr | — |
| Otherunder Preferred Stock Dividend | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Income | 0.87 Cr | 0.75 Cr | 0.58 Cr | 0.80 Cr | — |
| Minority Interests | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Income Including Noncontrolling Interests | 0.87 Cr | 0.75 Cr | 0.58 Cr | 0.80 Cr | — |
| Net Income Extraordinary | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Income Discontinuous Operations | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Income Continuous Operations | 0.87 Cr | 0.75 Cr | 0.58 Cr | 0.80 Cr | — |
| Tax Provision | 0.29 Cr | 0.24 Cr | 0.20 Cr | 0.24 Cr | — |
| Pretax Income | 1.16 Cr | 0.99 Cr | 0.78 Cr | 1.04 Cr | — |
| Other Non Operating Income Expenses | 0.34 Cr | 0.28 Cr | 0.20 Cr | 0.11 Cr | — |
| Special Income Charges | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Non Operating Interest Income Expense | -0.07 Cr | -0.09 Cr | 0.09 Cr | 0.04 Cr | — |
| Interest Expense Non Operating | 0.07 Cr | 0.09 Cr | 0.04 Cr | 42938.00 | — |
| Operating Income | 0.89 Cr | 0.80 Cr | 0.63 Cr | 0.96 Cr | — |
| Operating Expense | 3.42 Cr | 3.10 Cr | 2.44 Cr | 2.41 Cr | — |
| Other Operating Expenses | 1.97 Cr | 1.65 Cr | 0.08 Cr | 0.10 Cr | — |
| Depreciation And Amortization In Income Statement | 0.11 Cr | 0.11 Cr | 0.13 Cr | 0.13 Cr | — |
| Depreciation Income Statement | 0.11 Cr | 0.11 Cr | 0.13 Cr | 0.13 Cr | — |
| Gross Profit | 4.32 Cr | 3.89 Cr | 3.07 Cr | 3.38 Cr | — |
| Cost Of Revenue | 10.68 Cr | 11.29 Cr | 9.00 Cr | 10.71 Cr | — |
| Total Revenue | 15.00 Cr | 15.19 Cr | 12.07 Cr | 14.09 Cr | — |
| Operating Revenue | 15.00 Cr | 15.19 Cr | 12.07 Cr | 14.09 Cr | — |
| Interest Income | — | 0.18 Cr | 0.14 Cr | 0.07 Cr | 0.04 Cr |
| Rent Expense Supplemental | — | 0.24 Cr | 0.30 Cr | 0.20 Cr | 0.22 Cr |
| Diluted Average Shares | — | 0.30 Cr | 0.30 Cr | 0.30 Cr | 0.30 Cr |
| Basic Average Shares | — | 0.30 Cr | 0.30 Cr | 0.30 Cr | 0.30 Cr |
| Diluted EPS | — | 2.50 | 1.93 | 2.69 | 2.77 |
| Basic EPS | — | 2.50 | 1.93 | 2.69 | 2.77 |
| Total Other Finance Cost | — | 0.03 Cr | 0.02 Cr | 0.02 Cr | 0.01 Cr |
| Interest Income Non Operating | — | 0.18 Cr | 0.14 Cr | 0.07 Cr | 0.04 Cr |
| Selling General And Administration | — | 0.91 Cr | 0.65 Cr | 0.80 Cr | 0.74 Cr |
| Selling And Marketing Expense | — | 0.45 Cr | 0.29 Cr | 0.30 Cr | 0.35 Cr |
| General And Administrative Expense | — | 0.46 Cr | 0.36 Cr | 0.50 Cr | 0.39 Cr |
| Rent And Landing Fees | — | 0.24 Cr | 0.30 Cr | 0.20 Cr | 0.22 Cr |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Ishita Drugs & Industries Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.